Skip to content
Brand AI

Bristol Myers Squibb

Controversies

Controversies tied to this brand in public sources. A listing is not a finding of fault.

Back to profile4 entries

  1. 2022

    Bristol Myers Squibb sues AstraZeneca over cancer-treatment patents

    Lawsuit filed

    Bristol Myers Squibb sued AstraZeneca in Delaware federal court, alleging that AstraZeneca's use of Imfinzi to treat lung and bladder cancer infringes patents related to Opdivo. Bristol Myers sought monetary damages.

    Company response

    • Ongoing disclosure — AstraZeneca

      An AstraZeneca spokesperson said on Friday that the company was reviewing the complaint and would respond "at the appropriate time."

    Source excerpt

    • Bristol Myers Squibb Co, in a lawsuit made public on Friday, said AstraZeneca's cancer treatment Imfinzi violates patents related to its blockbuster cancer drug Opdivo.
    • The lawsuit https://tmsnrt.rs/3ieYLvz in Delaware federal court said that the use of Imfinzi to treat lung and bladder cancer infringes several patents on Bristol's immunotherapy Opdivo.
    • Bristol asked the Delaware court for an undisclosed amount of monetary damages.
    Source

  2. 2020

    China suspends imports, sales and use of Bristol Myers Squibb paclitaxel product

    Ban or restriction

    In March 2020, China's National Medical Products Administration announced the suspension of imports, sales and use of Bristol Myers Squibb's albumin-bound paclitaxel product. The agency said the action was based on inspection findings at a U.S. contract manufacturing facility. The announcement identified the product as albumin-bound paclitaxel and described the measure as a suspension covering import, sale and use in China. The notice did not specify further details beyond the inspection findings at the contract manufacturing site as the basis for the decision.

    Source excerpt

    • 公司于3月25日获悉，国家药品监督管理局宣布暂停进口、销售和使用美国新基公司(现隶属百时美施贵宝)注射用紫杉醇(白蛋白结合型)产品的决定。此项决定是基于对百时美施贵宝一家位于美国的合同生产机构的核查结果做出的。
    Source

  3. 2017

    Merck settles PD-1 patent litigation with BMS and Ono

    Settlement

    Merck agreed to pay Bristol-Myers Squibb and Ono Pharmaceutical $625 million and royalties on Keytruda sales to settle patent infringement litigation concerning PD-1 inhibitors. The agreement provided for dismissal of the patent litigation filed against Merck.

    Source excerpt

    • The US drugmaker has agreed to pay Bristol-Myers Squibb and Ono Pharmaceutical $625m to settle the patent infringement litigation – focusing on intellectual property in the area of PD-1 inhibitors – and will also pay a 6.5% royalty on sales of Keytruda (pembrolizumab) through to December 2023.
    • Phil Taylor 23rd January 2017
    Source

  4. 2006

    Plavix distribution and channel-stuffing controversy

    The FBI searched BMS corporate offices in connection with allegations involving Plavix distribution, channel stuffing, and generic competition. A court-appointed monitor urged removal of CEO Peter Dolan, who stepped down. The deferred-prosecution agreement ended in 2007 without further Department of Justice action on the matters covered by it.

    Source